We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $4.46B
This Fund
S&P 500
This Quarter Est. Return
-11.93%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$3.06B
AUM Growth
+$226M
Cap. Flow
+$653M
Cap. Flow %
21.38%
Top 10 Hldgs %
83.2%
Holding
374
New
73
Increased
133
Reduced
109
Closed
49

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$334M
2
JD icon
JD.com
JD
+$84.6M
3
BIDU icon
Baidu
BIDU
+$84.3M
4
NTES icon
NetEase
NTES
+$50.9M
5
PDD icon
Pinduoduo
PDD
+$50.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 63.45%
2 Communication Services 21.89%
3 Technology 6.77%
4 Healthcare 2.16%
5 Financials 1.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GLW icon
201
Corning
GLW
$128B
$293K 0.01%
7,925
+444
+6% +$17.3K
PTCT icon
202
PTC Therapeutics
PTCT
$5.84B
$292K 0.01%
+7,830
New +$302K
SYK icon
203
Stryker
SYK
$127B
$291K 0.01%
1,089
-123
-10% -$31.8K
EXEL icon
204
Exelixis
EXEL
$13.5B
$290K 0.01%
12,780
+2,416
+23% +$47.2K
TGTX icon
205
TG Therapeutics
TGTX
$8.31B
$290K 0.01%
30,483
+20,017
+191% +$232K
ALKS icon
206
Alkermes
ALKS
$7.97B
$289K 0.01%
+11,003
New +$273K
IRWD icon
207
Ironwood Pharmaceuticals
IRWD
$682M
$289K 0.01%
22,986
+7,384
+47% +$84.6K
RTX icon
208
RTX Corp
RTX
$285B
$289K 0.01%
2,920
-407
-12% -$38.6K
ENPH icon
209
Enphase Energy
ENPH
$4.92B
$288K 0.01%
1,427
+112
+9% +$17.6K
SRNE
210
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$287K 0.01%
123,048
+95,216
+342% +$297K
SAGE
211
DELISTED
Sage Therapeutics
SAGE
$286K 0.01%
+8,634
New +$325K
INSM icon
212
Insmed
INSM
$25.8B
$285K 0.01%
+12,116
New +$282K
PM icon
213
Philip Morris
PM
$299B
$285K 0.01%
3,037
-402
-12% -$40.2K
DNLI icon
214
Denali Therapeutics
DNLI
$3.84B
$284K 0.01%
+8,827
New +$304K
RCL icon
215
Royal Caribbean
RCL
$74.9B
$284K 0.01%
3,388
-39
-1% -$3.07K
ZTS icon
216
Zoetis
ZTS
$32.1B
$284K 0.01%
1,504
-72
-5% -$14.2K
CCXI
217
DELISTED
ChemoCentryx, Inc.
CCXI
$284K 0.01%
+11,309
New +$318K
ALNY icon
218
Alnylam Pharmaceuticals
ALNY
$31.6B
$283K 0.01%
+1,732
New +$264K
SPGI icon
219
S&P Global
SPGI
$131B
$283K 0.01%
691
+162
+31% +$66K
NBIX icon
220
Neurocrine Biosciences
NBIX
$15.7B
$282K 0.01%
+3,005
New +$255K
ACAD icon
221
Acadia Pharmaceuticals
ACAD
$5.01B
$280K 0.01%
+11,573
New +$280K
NTRA icon
222
Natera
NTRA
$47.1B
$280K 0.01%
+6,882
New +$414K
OPK icon
223
Opko Health
OPK
$1.11B
$280K 0.01%
81,338
+53,299
+190% +$188K
ZNTL icon
224
Zentalis Pharmaceuticals
ZNTL
$361M
$280K 0.01%
+6,079
New +$328K
HZNP
225
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$280K 0.01%
+2,663
New +$260K

Similar funds

E Fund Management's Q1 2022 Portfolio in Review

As of Q1 2022, E Fund Management held 374 positions worth $3.06B, up 8% from $2.83B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

E Fund Management deployed $653M of net new capital in Q1 2022, opening 73 new positions and adding to 133 existing holdings. Its largest new stake was Natera: 6,882 shares worth $280K.

By sector, the portfolio is most concentrated in Consumer Discretionary at 63% of assets, up from 61% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was United States Brent Oil Fund, an estimated $6.01M trimmed.

  • E Fund Management's largest Q1 2022 buy was Natera: 6,882 shares worth $280K.
  • E Fund Management added most to Alibaba in Q1 2022, an estimated $334M increase.
  • E Fund Management's biggest Q1 2022 reduction was United States Brent Oil Fund, cutting an estimated $6.01M.
  • E Fund Management fully exited NIO in Q1 2022, selling an estimated $10.7M.
  • E Fund Management's ten largest holdings make up 83% of its $3.06B portfolio in Q1 2022.
  • E Fund Management opened 73 new positions and closed 49 in Q1 2022.
  • E Fund Management's portfolio value rose 8% quarter-over-quarter to $3.06B.

Based on E Fund Management's 13F filing for Q1 2022, filed 12 May 2022.